Brought to you by 
Swiss spec pharma ObsEva completes $90mm IPO on Nasdaq
28 Mar 2017
Executive Summary
Three months after an October 2016 announcement of its intent to go public in the US, Swiss women’s health company ObsEva SA (small-molecule therapeutics for serious conditions in reproductive health and pregnancy) netted $90mm in an IPO on Nasdaq of 6.45mm shares at $15, the mid-point of its anticipated range.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Swiss spec pharma ObsEva completes $90mm IPO on Nasdaq
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice